Patients with RA, Number | Population comparators, Number | HR (95% CI) | |
Overall | 190 | 1191 | 0.80 (0.68 to 0.93) |
Exposure variants | |||
RA, 18–49 years | 18 | 155 | 0.59 (0.36 to 0.97) |
RA, 50–75 years | 146 | 841 | 0.87 (0.73 to 1.03) |
RA, >75 years | 26 | 195 | 0.68 (0.45 to 1.03) |
RA 18–50 and breast cancer <50 years | 9 | 53 | 0.86 (0.42 to 1.75) |
Seronegative RA | 55 | 346 | 0.77 (0.58 to 1.02) |
Seropositive RA | 124 | 772 | 0.81 (0.67 to 0.98) |
Outcome variants | |||
Breast cancer, 18–50 years | 9 | 102 | 0.47 (0.24 to 0.93) |
Breast cancer, >50 years | 181 | 1089 | 0.83 (0.71 to 0.97) |
Stage 0 | 12 | 97 | 0.63 (0.34 to 1.14) |
Stage 1 | 85 | 490 | 0.87 (0.69 to 1.09) |
Stage 2 | 60 | 375 | 0.80 (0.61 to 1.05) |
Stage 3 | 4 | 41 | 0.49 (0.17 to 1.36) |
Stage 4 | 6 | 30 | 0.99 (0.41 to 2.39) |
HRT, hormone replacement therapy; RA, rheumatoid arthritis.